Quentin V.

Quentin V. has a diverse and extensive work experience in the fields of computational biology and artificial intelligence (AI) drug discovery. Quentin started their career as a Boursier post-doctorat at the Ottawa Hospital Research Institute, where they focused on stem cell fate decision and pluripotency maintenance. This experience allowed him to gain insight into the practical aspects of modeling and computational approaches in biology. Quentin then moved on to work as a Scientific Consultant at Insilicoscreen, where they developed a computational workflow to study signaling pathways and gene regulatory networks. Currently, Quentin is the Head of the "Almost Human" Group at Insilico Medicine, an AI drug discovery company. The company has achieved significant milestones and raised substantial funding, and Quentin's role involves utilizing AI technology to accelerate the drug discovery process for pharmaceutical companies globally.

Quentin V. completed their education in the field of Physical Sciences at the Université libre de Bruxelles. Quentin obtained their Bachelor's degree and Master degree from 2002 to 2006. Quentin then continued their academic journey at the same university, pursuing a Doctor of Philosophy (PhD) in Theoretical Physics from 2006 to 2010.